 |
Alimera Sciences Receives Complete Response Letter From FDA for ILUVIEN®
Nov 11, 2011
|
15.9 KB |
|
| |
ATLANTA, Nov. 11, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FD...
|
|
Alimera Sciences to Present at November Conferences
Nov 7, 2011
|
8.8 KB |
|
| |
ATLANTA, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that management will be attending the following investor conferences in November:
The 20...
|
|
Alimera Sciences Reports Third Quarter 2011 Financial Results
Nov 3, 2011
|
22.4 KB |
|
| |
Alimera will host a Conference Call at 4:30 PM ET Today to discuss Financial Results
Cash, Cash Equivalents and Investments in Marketable Securities at September 30, 2011 Totaled $38.6 Million
ATLANTA, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in ...
|
|
Alimera Sciences to Release Third Quarter Fiscal Year 2011 Financial Results
Oct 20, 2011
|
8.5 KB |
|
| |
ATLANTA, Oct. 20, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its third fiscal quarter 2011 financial results after the market close on Thursd...
|
|
Alimera Sciences Highlights 36-Month FAME™ Study Data on ILUVIEN® at AAO 2011 Annual Meeting
Oct 12, 2011
|
17.1 KB |
|
| |
ATLANTA, Oct. 12, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that 36-month data from its Phase 3 FAME™ study of ILUVIEN® will be presented at the annu...
|
|
Alimera Sciences to Present at September Conferences
Sep 1, 2011
|
8.7 KB |
|
| |
ATLANTA, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer of Alimera, will present at the following inves...
|
|
Alimera Sciences Reports Second Quarter 2011 Financial Results
Aug 4, 2011
|
22.0 KB |
|
| |
Alimera will host a Conference Call at 4:30 PM ET Today to discuss Financial Results and provide an Update on Regulatory Developments
Cash, Cash Equivalents and Investments in Marketable Securities at June 30, 2011 Totaled $44.4 Million
ATLANTA, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a bi...
|
|
Alimera Sciences Appoints James R. Largent to Its Board of Directors
Aug 1, 2011
|
12.2 KB |
|
| |
ATLANTA, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that James R. Largent has joined its Board of Directors. Mr. Largent, a consultant in the medical devi...
|
|
Alimera Sciences to Release Second Quarter Fiscal Year 2011 Financial Results
Jul 21, 2011
|
8.5 KB |
|
| |
ATLANTA, July 21, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second fiscal quarter 2011 financial results after the market close on Thurs...
|
|
Alimera Sciences to Present at 2011 BIO Business Forum
Jun 23, 2011
|
7.9 KB |
|
| |
ATLANTA, June 23, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer of Alimera, will present at the 2011 BIO Busine...
|
|
Alimera Sciences Extends and Expands Credit Facility
May 17, 2011
|
14.1 KB |
|
| |
ATLANTA, May 17, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced modifications to its credit facility with lenders Midcap Financial, LLC and Silicon Valley Bank. The cre...
|
|
Alimera Sciences Announces Resubmission of New Drug Application for ILUVIEN®
May 13, 2011
|
12.3 KB |
|
| |
ATLANTA, May 13, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the resubmission on May 12, 2011 of its New Drug Application for the investigational drug ILUVIEN® ...
|
|
Alimera Sciences Reports First Quarter 2011 Financial Results and
Reviews New 36 Month Safety and Efficacy Data
From the Phase 3 Fame™ Study of Iluvien®
May 5, 2011
|
22.5 KB |
|
| |
ATLANTA, May 5, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2011. Alimera ...
|
|
Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fame™ Study of Iluvien® in Patients With Diabetic Macular Edema Presented at the 2011 Arvo Annual Meeting
May 3, 2011
|
16.8 KB |
|
| |
Peak Efficacy of 33.6% of Patients in Trial A, (p...
|
|
Alimera Sciences Announces Upcoming Company Events
Apr 26, 2011
|
10.5 KB |
|
| |
FAME™ Investigator, Dr. Andrew Antoszyk, to Review New Efficacy and Safety Data of ILUVIEN® at the 2011 ARVO Annual Meeting
Company to Hold Conference Call to Discuss First Quarter, 2011 Financial Results and Review New Study Data
ATLANTA, April 26, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"...
|
|
Alimera Sciences Adds Dr. Glen Bradley to Its Board of Directors
Apr 18, 2011
|
12.6 KB |
|
| |
ATLANTA, April 18, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dr. Glen Bradley has joined its Board of Directors and the Audit Committee of the Board. Dr. Br...
|
|
Alimera Sciences to Present at March Conferences
Feb 24, 2011
|
9.3 KB |
|
| |
ATLANTA, Feb. 24, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that management will be attending the following investor conferences in March:
The Citi...
|
|
Alimera Sciences Reports Fourth Quarter 2010 Financial Results
Feb 10, 2011
|
23.4 KB |
|
| |
Reiterates Positive 36-Month Results From the Completed Phase 3 FAME™ Study of ILUVIEN® in Patients With Diabetic Macular Edema
Cash, Cash Equivalents and Investments at December 31, 2010 Totaled $54.8 Million
ATLANTA, Feb. 10, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company th...
|
|
Alimera Sciences to Present at BIO CEO & Investor Conference
Feb 8, 2011
|
8.3 KB |
|
| |
ATLANTA, Feb. 8, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the 13th Annual BIO CEO & Inves...
|
|
Alimera Sciences to Hold Conference Call to Discuss Fourth Quarter and Full Year 2010 Financial Results
Feb 4, 2011
|
8.7 KB |
|
| |
ATLANTA, Feb. 4, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and full year 2010 financial results after the market close on...
|
|
|
